Fig. 6: Subclonal differences in Gain/Amp1q. | Nature Communications

Fig. 6: Subclonal differences in Gain/Amp1q.

From: 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma

Fig. 6

Patient sample 0661-533 clustering based on RNA (A), ATAC (B), WNN integrated RNA and ATAC (C). D WGS based CNV profile for 0661-533. E CNVs inferred from scRNA-seq data for 0661-533. F Increased expression of PBX1, RBBP5, and PHF19 in Amp1q clones from 0661-533 (One-sided t-test: RBBP5 P = 1.54E−2, PBX1 P = 1.27E−2, PHF19 P = 3.55E−3). G Increase in G2M and S phases of cell cycle for cells in Amp1q clones from 0661-533 (Fisher’s exact P = 8.47E−26). Patient sample 0661-1043 clustering based on RNA (H), ATAC (I), WNN integrated RNA and ATAC (J). K WGS based CNV profile. L CNVs inferred from scRNA-seq data. M Increased expression of PBX1, RBBP5, and PHF19 in Amp1q clones (One-sided t-test: RBBP5 P = 2.44E−11, PBX1 P = 9.38E−170, PHF19 P = 2.24E−6). N Increase in G2M and S phases of cell cycle for cells in Amp1q clones from 0661-1043 (Fisher’s exact P = 3.69E−12). Fisher’s exact test significance levels are: P < 0.1: (\(\cdot\)), P < 0.05: *, P < 0.01 (**), P < 0.001 (***).

Back to article page